4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
20.58
-0.76 (-3.56%)
Jul 2, 2024, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 147 employees as of December 31, 2023. The number of employees increased by 7 or 5.00% compared to the previous year.
Employees
147
Change (1Y)
7
Growth (1Y)
5.00%
Revenue / Employee
$139,129
Profits / Employee
-$711,265
Market Cap
1.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 147 | 7 | 5.00% |
Dec 31, 2022 | 140 | 16 | 12.90% |
Dec 31, 2021 | 124 | 41 | 49.40% |
Dec 31, 2020 | 83 | 26 | 45.61% |
Jun 30, 2019 | 57 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
AtriCure | 1,050 |
Xencor | 280 |
Collegium Pharmaceutical | 197 |
Prothena Corporation | 173 |
Verona Pharma | 79 |
FDMT News
- 24 days ago - 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting - GlobeNewsWire
- 26 days ago - 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference - GlobeNewsWire
- 4 weeks ago - 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference - GlobeNewsWire
- 7 weeks ago - 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - 4DMT to Participate in Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - 4DMT Announces Presentations at ARVO 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis - GlobeNewsWire
- 4 months ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire